SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SCHEDULE OF UNREALIZED GAINS AND LOSSES

			Cumulative		Cumulative
			Gross		Gross
	Initial		Unrealized		Unrealized		Fair
	Book Value		Gains		Losses		Value
June 30, 2023 and December 31, 2022
Investment in GMP Bio (equity securities)	$	22,640,519	$	-	$	-	$	22,640,519
Total	$	22,640,519	$	-	$	-	$	22,640,519

SUMMARY OF CHANGES IN FAIR VALUE OF LONG-TERM INVESTMENT IN EQUITY SECURITIES

	June 30, 2023		December 31, 2022
Balance at January 1, 2023 and 2022	$	22,640,519	$	-
Contribution at cost basis		-		5,689,042
Gain on derecognition of non-financial asset		-		16,591,477
Change in fair value		-		-
Balance at June 30, 2023 and December 31, 2022	$	22,640,519	$	22,640,519

SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of June 30, 2023 and 2022:

	June 30, 2023		June 30, 2022
	Conversion Feature		Conversion Feature
Balance at January 1, 2023 and 2022	$	198,140	$	340,290
New derivative liability				-
Reclassification to additional paid in capital from conversion of debt to common stock				-
Change in fair value		327,594		67,922
Balance at June, 2023 and 2022	$	525,734	$	408,212

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES

	June 30, 2023			June 30, 2022
	Key			Key
	Assumptions			Assumptions
	for fair value			for fair value
	of conversions			of conversions
Risk free interest		5.4	%		0.17% -1.03%
Market price of share	$	0.03		$	0.17-0.23
Life of instrument in years		0.01			0.01 – 0.33
Volatility		171.25	%		107.50%-109.40%
Dividend yield		0	%		0	%